Aurobindo Pharma will seek approval from its shareholders for an enabling resolution to raise up to $600 million (about ₹3,980 crore). In January, its shareholders had approved a $350-million QIP issue but the company did not raise the funds due to volatile market.
The resolution had a validity period of one year. Hence, the board is again seeking shareholders’ nod for the revised amount, proposed to be raised either through FCCBs, ADRs, GDRs, QIP or QFIs.